Your browser doesn't support javascript.
loading
High-Dose Opioid Prescribing in Individuals with Acute Pain: Assessing the Effects of US State Opioid Policies.
Bradford, Ashley C; Nguyen, Thuy; Schulson, Lucy; Dick, Andrew; Gupta, Sumedha; Simon, Kosali; Stein, Bradley D.
Afiliação
  • Bradford AC; School of Public Policy, Georgia Institute of Technology, Atlanta, GA, USA. bradford@gatech.edu.
  • Nguyen T; School of Public Health, Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
  • Schulson L; RAND Corporation, Boston, MA, USA.
  • Dick A; Department of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA.
  • Gupta S; RAND Corporation, Boston, MA, USA.
  • Simon K; Department of Economics, Indiana University, Indianapolis, IN, USA.
  • Stein BD; O'Neill School of Public and Environmental Affairs, Indiana University, Bloomington, IN, USA.
J Gen Intern Med ; 2024 Jul 19.
Article em En | MEDLINE | ID: mdl-39028403
ABSTRACT

BACKGROUND:

How state opioid policy environments with multiple concurrent policies affect opioid prescribing to individuals with acute pain is unknown.

OBJECTIVE:

To examine how prescription drug monitoring programs (PDMPs), pain management clinic regulations, initial prescription duration limits, and mandatory continued medical education affected total and high-dose prescribing.

DESIGN:

A county-level multiple-policy difference-in-difference event study framework.

SUBJECTS:

A total of 2,425,643 individuals in a large national commercial insurance deidentified claims database (aged 12-64 years) with acute pain diagnoses and opioid prescriptions from 2007 to 2019. MAIN

MEASURES:

The total number of acute pain opioid treatment episodes and number of episodes containing high-dose (> 90 morphine equivalent daily dosage (MEDD)) prescriptions. KEY

RESULTS:

Approximately 7.5% of acute pain episodes were categorized as high-dose episodes. Prescription duration limits were associated with increases in the number of total episodes; no other policy was found to have a significant impact. Beginning five quarters after implementation, counties in states with pain management clinic regulations experienced a sustained 50% relative decline in the number of episodes containing > 90 MEDD prescriptions (95 CIs (Q5 - 0.506, - 0.144; Q12 - 1.000, - 0.290)). Mandated continuing medical education regarding the treatment of pain was associated with a 50-75% relative increase in number of high-dose episodes following the first year-and-a-half of enactment (95 CIs (Q7 0.351, 0.869; Q12 0.413, 1.107)). Initial prescription duration limits were associated with an initial relative reduction of 25% in high-dose prescribing, with the effect increasing over time (95 CI (Q12 - 0.967, - 0.335). There was no evidence that PDMPs affected high-dose opioids dispensed to individuals with acute pain. Other high-risk prescribing indicators were explored as well; no consistent policy impacts were found.

CONCLUSIONS:

State opioid policies may have differential effects on high-dose opioid dispensing in individuals with acute pain. Policymakers should consider effectiveness of individual policies in the presence of other opioid policies to address the ongoing opioid crisis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article